Viking Therapeutics (VKTX) Non Operating Investment Income (2024 - 2026)
Viking Therapeutics' (VKTX) quarterly Non Operating Investment Income came in at $30000.0 in Q2 2026, up 650.0% year-over-year from $4000.0 in Q2 2025, and up 650.0% quarter-over-quarter from $4000.0 in Q2 2025.
Powered by 
Analysis
Viking Therapeutics (VKTX) Non Operating Investment Income (2024 - 2026) Analysis & Trends
Viking Therapeutics has disclosed Non Operating Investment Income across 3 years of filings, most recently posting $30000.0 for Q2 2026.
- In Q2 2026, Non Operating Investment Income rose 650.0% year-over-year to $30000.0; the TTM figure through Jun 2026 stood at $144000.0 (up 24.14% YoY), while the FY2025 annual figure was $55000.0, down 50.89% from the prior year.
- Non Operating Investment Income came in at $30000.0 for Q2 2026 at Viking Therapeutics, up from $4000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $109000.0 in Q3 2024 to a low of $1000.0 in Q4 2024.
- Average Non Operating Investment Income over 3 years is $29200.0, with a median of $4000.0 recorded in 2025.
- Year-over-year, Non Operating Investment Income soared 100.0% in 2025 and surged 650.0% in 2026.
- Over 3 years, Non Operating Investment Income stood at $1000.0 in 2024, then surged by 300.0% to $4000.0 in 2025, then surged by 650.0% to $30000.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Investment Income figures were $30000.0 in Q2 2026, $4000.0 in Q2 2025, and $1000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Op. Investment Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.01 Bn | 628.25 Bn | 17.26 Bn | - |
| 2 | AbbVie | 468.55 Bn | 462.03 Bn | 12.70 Bn | - |
| 3 | Merck | 365.49 Bn | 358.40 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 272.39 Bn | 265.10 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 253.18 Bn | 247.96 Bn | 12.86 Bn | - |
| 6 | Amgen | 219.53 Bn | 205.54 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 187.85 Bn | 184.59 Bn | 6.22 Bn | - |
| 8 | Pfizer | 160.56 Bn | 149.16 Bn | 10.94 Bn | - |
| 9 | Vertex Pharmaceuticals | 130.81 Bn | 122.96 Bn | 2.84 Bn | - |
| 10 | Viking Therapeutics | 4.86 Bn | 4.86 Bn | - | 30,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 109,000.00 |
| Jun 30, 2024 | 2,000.00 |
API Access
Viking Therapeutics Non Operating Investment Income API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=VKTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "non-operating-investment-income", "ticker": "VKTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=VKTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();